ALTERITY THERAPEUTICS LTD

ATHE

Explore Our Financial Data > Companies > ALTERITY THERAPEUTICS LTD
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ATHE
CIK0001131343
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

AddressLEVEL 3, 460 BOURKE STREET, MELBOURNE, C3, VIC 3000
Website alteritytherapeutics.com
Phone61 3 9349 4906
CEODavid A. Stamler
Employees10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-12.74 million
Net Income$-12.77 million
Net Income to Common$-12.77 million
EPSN/A
View All
Balance Sheet
Cash$8.44 million
Assets$12.84 million
Liabilities$3.62 million
Common Equity$18.43 million
Liabilities & Equity$22.05 million
View All
Cash Flow Statement
Net Income$-12.77 million
Cash From Operating Activities$-2.39 million
Cash From Investing Activities$-3,821.00
Cash From Financing Activities$0.00
Change in Cash$-2.27 million
View All
Calculations
NOPAT$-11.04 million
EBITDA$-12.92 million
Price to EarningsN/A
Price to Book$21.18
ROE-52.30%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will

Article Link

Alterity Therapeutics Prominently Featured at the International MSA Congress

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying

Article Link

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

ATH434 Phase 2 Data to be Presented at Opening Plenary SessionMELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity’s clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MS

Article Link

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

– Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment o

Article Link

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacyPhase 2 data featured in an oral presentation at the American Academy of Neurology Annual MeetingATH434-202 open-label trial in advanced MSA completed in March 2025Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarter MELBOURNE, Australia and SAN FRANCISCO, April 30, 2025

Article Link